ResMed Inc. (0KW4)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 239.40 |
|---|---|
| 52-week range | 180.06 – 274.91 |
| Return, 1 month / 3 months | +4.9% / +20.7% |
| Return, 1 year / 3 years | −13.3% / +79.2% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 28.7% |
| Worst drawdown (1 year) | -32.6% |
| Average daily value traded | 0.10M USD |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ResMed Inc. designs and manufactures devices and masks used to treat sleep apnoea and other respiratory conditions, including continuous positive airway pressure machines and ventilation equipment. It also offers software and connected-care services that help clinicians and patients monitor therapy. Its customers include home medical equipment providers, hospitals, sleep clinics and individual patients. The company is based in San Diego, California, and serves markets around the world.
The shares are listed on the London Exchange in UK under the code 0KW4, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
ResMed Inc. (0KW4) trades on the London Exchange in UK. It last closed at USD 239.40 on 19 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,820 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.3% and over the last three months it rose 20.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.7% | ||
| From 52-week high | -11.9% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 20.7% | ||
| 6-month return | 5.6% | ||
| 12-month return, skipping the last month | -17.3% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.6% | ||
| Liquidity | 30 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.5% |
|---|---|
| 1 month | +4.9% |
| 3 months | +20.7% |
| 6 months | +5.6% |
| 1 year | −13.3% |
| 3 years | +79.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 226.91 / 224.47 |
|---|---|
| Golden / death cross (60 days) | Golden, 5 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.22 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Aug 2026 | USD 0.6600 |
| 14 May 2026 | USD 0.6000 |
| 11 Feb 2026 | USD 0.6000 |
| 12 Nov 2025 | USD 0.6000 |
| 13 Aug 2025 | USD 0.6000 |
| 7 May 2025 | USD 0.5300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.